The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease

被引：1
|
作者：
Kawada, Tomoyuki [1 ]
机构：
[1] Nippon Med Sch, Dept Hyg & Publ Hlth, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan
来源：
CLINICAL AND EXPERIMENTAL NEPHROLOGY | 2016年 / 20卷 / 01期
关键词：
Estimated glomerular filtration rate; Autosomal dominant polycystic kidney disease; Tolvaptan; Validity;
D O I：
10.1007/s10157-015-1134-y
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：147 / 148
页数：2
相关论文
共 50 条
  • [21] Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Pharmacokinetics and Implications for Practice
    Hines, Cheryl B.
    Hooper, Gwendolyn L.
    Collins-Yoder, Angela
    NEPHROLOGY NURSING JOURNAL, 2020, 47 (02) : 145 - 150
  • [22] Kidney volume and function in autosomal dominant polycystic kidney disease
    Eiji Higashihara
    Kikuo Nutahara
    Takatsugu Okegawa
    Toshihide Shishido
    Mitsuhiro Tanbo
    Kuninori Kobayasi
    Toshiaki Nitadori
    Clinical and Experimental Nephrology, 2014, 18 : 157 - 165
  • [23] Kidney volume and function in autosomal dominant polycystic kidney disease
    Higashihara, Eiji
    Nutahara, Kikuo
    Okegawa, Takatsugu
    Shishido, Toshihide
    Tanbo, Mitsuhiro
    Kobayasi, Kuninori
    Nitadori, Toshiaki
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2014, 18 (01) : 157 - 165
  • [24] Pro: Tolvaptan delays the progression of autosomal dominant polycystic kidney disease
    Torres, Vicente E.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 (01) : 30 - 34
  • [25] Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Three Years' Experience
    Higashihara, Eiji
    Torres, Vicente E.
    Chapman, Arlene B.
    Grantham, Jared J.
    Bae, Kyongtae
    Watnick, Terry J.
    Horie, Shigeo
    Nutahara, Kikuo
    Ouyang, John
    Krasa, Holly B.
    Czerwiec, Frank S.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 6 (10): : 2499 - 2507
  • [26] Autosomal Dominant Polycystic Kidney Disease Inflammation Biomarkers in the Tolvaptan Era
    Lapao, Tania
    Barata, Rui
    Jorge, Cristina
    Flores, Carlos
    Calado, Joaquim
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (03)
  • [27] THE BURDEN OF TOLVAPTAN TREATMENT FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
    Muto, Satoru
    Kawano, Haruna
    Sugiura, Syou-ichiro
    Kitamura, Kousuke
    Kimura, Masaki
    Isotani, Shuji
    Ide, Hisamitsu
    Yamaguchi, Raizo
    Horie, Shigeo
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
  • [28] Commentary: Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) - an update
    Gittus, Matt
    Haley, Helen
    Harris, Tess
    Borrows, Sarah
    Padmanabhan, Neal
    Gale, Danny
    Simms, Roslyn
    Williams, Terri
    Acquaye, Aaron
    Wong, Alisa
    Chan, Melanie
    Lee, Eduardo
    Ong, Albert C. M.
    BMC NEPHROLOGY, 2025, 26 (01)
  • [29] Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
    Blanchette, Christopher M.
    Gutierrez, Benjamin
    Friend, Keith
    ANNALS OF INTERNAL MEDICINE, 2014, 160 (02) : 142 - 143
  • [30] Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
    Erickson, Kevin F.
    Chertow, Glenn M.
    Goldhaber-Fiebert, Jeremy D.
    ANNALS OF INTERNAL MEDICINE, 2013, 159 (06) : 382 - +
12345